Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Cellular immune response to hepatitis-C-virus in subjects without viremia or seroconversion: is it important?

Abdelwahab SF.

Infect Agent Cancer. 2016 May 16;11:23. doi: 10.1186/s13027-016-0070-0. eCollection 2016. Review.

2.

Hepatitis Vaccines.

Ogholikhan S, Schwarz KB.

Vaccines (Basel). 2016 Mar 11;4(1). pii: E6. doi: 10.3390/vaccines4010006. Review.

3.

Anti-HCV antibody among newly diagnosed HIV patients in Ughelli, a suburban area of Delta State Nigeria.

Newton OE, Oghene OA, Okonko IO.

Afr Health Sci. 2015 Sep;15(3):728-36. doi: 10.4314/ahs.v15i3.5.

4.

Peginterferon plus Ribavirin for HIV-infected Patients with Treatment-Naïve Acute or Chronic HCV Infection in Taiwan: A Prospective Cohort Study.

Liu CH, Sheng WH, Sun HY, Hsieh SM, Lo YC, Liu CJ, Su TH, Yang HC, Liu WC, Chen PJ, Chen DS, Hung CC, Kao JH.

Sci Rep. 2015 Nov 30;5:17410. doi: 10.1038/srep17410.

5.

Development of an In-House TaqMan Real Time RT-PCR Assay to Quantify Hepatitis C Virus RNA in Serum and Peripheral Blood Mononuclear Cells in Patients With Chronic Hepatitis C Virus Infection.

Khalvati Fahlyani B, Behzad-Behbahani A, Taghavi SA, Farhadi A, Salehi S, Adibzadeh S, Aboualizadeh F, Alavi P, Nikouyan N, Okhovat MA, Ranjbaran R, Rafiei Dehbidi GR, Shakibzadeh A.

Hepat Mon. 2015 Aug 31;15(8):e28895. doi: 10.5812/hepatmon.28895. eCollection 2015 Aug.

6.

Epitope Prediction Assays Combined with Validation Assays Strongly Narrows down Putative Cytotoxic T Lymphocyte Epitopes.

Ip PP, Nijman HW, Daemen T.

Vaccines (Basel). 2015 Mar 24;3(2):203-20. doi: 10.3390/vaccines3020203.

7.

Mathematical Modeling of Hepatitis C Prevalence Reduction with Antiviral Treatment Scale-Up in Persons Who Inject Drugs in Metropolitan Chicago.

Echevarria D, Gutfraind A, Boodram B, Major M, Del Valle S, Cotler SJ, Dahari H.

PLoS One. 2015 Aug 21;10(8):e0135901. doi: 10.1371/journal.pone.0135901. eCollection 2015.

8.

The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments.

Scott N, McBryde E, Vickerman P, Martin NK, Stone J, Drummer H, Hellard M.

BMC Med. 2015 Aug 20;13:198. doi: 10.1186/s12916-015-0440-2.

9.

Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection--the InC3 Study.

Sacks-Davis R, Grebely J, Dore GJ, Osburn W, Cox AL, Rice TM, Spelman T, Bruneau J, Prins M, Kim AY, McGovern BH, Shoukry NH, Schinkel J, Allen TM, Morris M, Hajarizadeh B, Maher L, Lloyd AR, Page K, Hellard M; InC3 study group.

J Infect Dis. 2015 Nov 1;212(9):1407-19. doi: 10.1093/infdis/jiv220. Epub 2015 Apr 15.

PMID:
25883387
10.

CD4+ T-Cell-Dependent Reduction in Hepatitis C Virus-Specific Neutralizing Antibody Responses After Coinfection With Human Immunodeficiency Virus.

Bailey JR, Dowd KA, Snider AE, Osburn WO, Mehta SH, Kirk GD, Thomas DL, Ray SC.

J Infect Dis. 2015 Sep 15;212(6):914-23. doi: 10.1093/infdis/jiv139. Epub 2015 Mar 9.

PMID:
25754978
11.

Immune mechanisms of vaccine induced protection against chronic hepatitis C virus infection in chimpanzees.

Verstrepen BE, Boonstra A, Koopman G.

World J Hepatol. 2015 Jan 27;7(1):53-69. doi: 10.4254/wjh.v7.i1.53. Review.

12.

Many hepatitis C reinfections that spontaneously clear may be undetected: Markov-chain Monte Carlo analysis of observational study data.

Sacks-Davis R, McBryde E, Grebely J, Hellard M, Vickerman P.

J R Soc Interface. 2015 Mar 6;12(104):20141197. doi: 10.1098/rsif.2014.1197.

13.

T cell responses in hepatitis C virus infection: historical overview and goals for future research.

Holz L, Rehermann B.

Antiviral Res. 2015 Feb;114:96-105. doi: 10.1016/j.antiviral.2014.11.009. Epub 2014 Nov 26. Review.

14.

Signatures of protective memory immune responses during hepatitis C virus reinfection.

Abdel-Hakeem MS, Bédard N, Murphy D, Bruneau J, Shoukry NH.

Gastroenterology. 2014 Oct;147(4):870-881.e8. doi: 10.1053/j.gastro.2014.07.005. Epub 2014 Jul 16.

15.

Immune control and failure in HCV infection--tipping the balance.

Dustin LB, Cashman SB, Laidlaw SM.

J Leukoc Biol. 2014 Oct;96(4):535-48. doi: 10.1189/jlb.4RI0214-126R. Epub 2014 Jul 11. Review.

16.

Hepatitis C virus hypervariable region 1 variants presented on hepatitis B virus capsid-like particles induce cross-neutralizing antibodies.

Lange M, Fiedler M, Bankwitz D, Osburn W, Viazov S, Brovko O, Zekri AR, Khudyakov Y, Nassal M, Pumpens P, Pietschmann T, Timm J, Roggendorf M, Walker A.

PLoS One. 2014 Jul 11;9(7):e102235. doi: 10.1371/journal.pone.0102235. eCollection 2014.

17.

Protective immunity against hepatitis C: many shades of gray.

Abdel-Hakeem MS, Shoukry NH.

Front Immunol. 2014 Jun 16;5:274. doi: 10.3389/fimmu.2014.00274. eCollection 2014. Review.

18.

Will there be a vaccine to prevent HCV infection?

Honegger JR, Zhou Y, Walker CM.

Semin Liver Dis. 2014 Feb;34(1):79-88. doi: 10.1055/s-0034-1371081. Epub 2014 Apr 29. Review.

19.

Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C?

Lee YA, Friedman SL.

Antiviral Res. 2014 Jul;107:23-30. doi: 10.1016/j.antiviral.2014.03.012. Epub 2014 Apr 12. Review.

20.

Hepatitis C virus NS3 mutations in haemophiliacs.

Lin MV, Charlton AN, Rouster SD, Zamor PJ, Sherman KE.

Haemophilia. 2014 Sep;20(5):659-65. doi: 10.1111/hae.12420. Epub 2014 Apr 3.

Items per page

Supplemental Content

Write to the Help Desk